Protheragen-ING Joins the DCAT Association

In exciting news, Protheragen-ING officially become a member of the Drug, Chemical & Associated Technologies (DCAT) Association.

This move marks a significant milestone for Protheragen-ING and highlights the company's commitment to collaboration, innovation, and growth within the global pharmaceutical community.

By joining forces with DCAT, Protheragen-ING aims to contribute to the advancement of drug development and manufacturing.

The Significance of DCAT

DCAT is a non-profit and member-supported global business development association.

The members are multinational companies directly involved in the entire pharmaceutical manufacturing value chain: from raw materials, intermediates, and active pharmaceutical ingredients to formulation development, pharmaceutical manufacturing, distribution, packaging, and related supply chain services.

DCAT has a unique membership model integrating innovative and generic drug manufacturers and suppliers of ingredients, development and manufacturing services and related technologies.

DCAT provides a platform for its member companies to foster collaboration, share industry knowledge and promote networking opportunities.

Protheragen-ING's membership in DCAT provides companies with a number of key benefits.

Collaboration and Innovation

Protheragen-ING's membership in the DCAT association marks an exciting chapter in our company's journey of further growth and innovation.

The decision to join DCAT emphasizes our commitment to collaboration and innovation. By becoming a member, we align ourselves with like-minded organizations dedicated to advancing drug development and manufacturing.